The frequency of Epstein-Barr virus among hemodialysis patients, Ahvaz, Iran

• Main Authors: Rahil Nahid Samiei, Shahab Mahmoudvand, Somayeh Shokri, Manoochehr Makvandi, Heshmatollah Shahbazian, Roya Pirmoradi, Shokouh Shayanpur, Kimia Makvandi, Sepideh Nowrozi
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2019-03-01
• Series: Iranian Journal of Microbiology
• Subjects: Epstein-Barr virus; Hemodialysis patients; Enzyme-linked immunosorbent assay
• Online Access: https://ijm.tums.ac.ir/index.php/ijm/article/view/1667

Background and Objectives: Epstein-Barr virus (EBV) has infected more than 90% of adults worldwide. EBV infection is asymptomatic in healthy individuals and is controlled by a robust immune response while in individuals with weakened immunesystems including Hemodialysis (HD) patients and transplant recipients leads to serious illnesses. This study was aimed to investigate the frequency of EBV among the HD patients. Materials and Methods: The cross-sectional study was carried out on 84 HD patients. These sera were checked for anti-EBV (VCA) IgG Ab assessment using enzyme-linked immunosorbent assay (ELISA). The DNA was extracted from the sera samples and tested for EBV DNA using nested PCR. Results: 52/84 (61.9%) of HD were males and 32/84 (38.1%) were females. The average age of participants was varying from 18 to 85 years while the mean age was 52 ± 1.57 SD years. 81 of 84 (96.42%); including 49/52 (94.23%) male and 32/32 (100%) female, were positive for anti-EBV (VCA) IgG antibody while 3 (3.58%) were negative. No significant differences were observed between the subjects regarding gender (P=0.28). EBV DNA was detected in 7 (8.33%) individuals, including 6 (11.53%) and 1 (3.12%) in male and female, respectively (P=0.24). Conclusion: Our study results showed that high prevalence of anti-EBV (VCA) IgG antibody (96.42%) were observed among the HD patients. Although the status of EBV latency was not performed, but it seems many of these patients are at risk of EBV-reactivation during the organ transplantation. As a result, it is recommended that the detection of EBNA-1 gene as a marker of EBV latency should be implemented for all HD patients to prevent EBV reactivation during organ transplantation.